The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to offer a greater substantial reduction in body weight and benefit metabolic marker